TY - JOUR T1 - Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: a meta-analysis. AU - Cheng,J, AU - Zhang,X, AU - Tian,J, AU - Li,Q, AU - Chen,J, PY - 2012/9/22/entrez PY - 2012/9/22/pubmed PY - 2013/2/23/medline SP - 917 EP - 23 JF - International journal of clinical practice JO - Int J Clin Pract VL - 66 IS - 10 N2 - OBJECTIVE: The pathogenesis of IgA nephropathy (IgAN) is still unknown. Combination therapy with angiotensin-converting enzyme inhibitors (ACEIs) plus angiotensin receptor blockers (ARBs) might provide more benefits to IgAN patients. We conducted a systematic review to assess the efficacy of combination therapy for IgAN. METHODS: The MEDLINE, EMBASE, the Cochrane Library and article reference lists were searched for randomised clinical trials (RCTs) which involved combination therapy ACEI plus ARB in only one arm. A meta-analysis was performed on the outcomes of proteinuria and renal function in IgAN patients. RESULTS: Six RCTs involving 109 patients were included in the review. Combined treatment with ACEI plus ARB was more effective than with ACEI/ARB alone for reducing daily proteinuria. This did not translate into an improvement in GFR. Patients receiving ACEI plus ARB therapy did not have an increased risk of hyperkalemia. CONCLUSIONS: The current cumulative evidence suggests that combination therapy ACEI plus ARB may provide more benefits to IgAN patients for reducing daily proteinuria. Long-term effects of these agents on renal outcomes, and safety need to be established. SN - 1742-1241 UR - https://www.unboundmedicine.com/medline/citation/22994326/Combination_therapy_an_ACE_inhibitor_and_an_angiotensin_receptor_blocker_for_IgA_nephropathy:_a_meta_analysis_ L2 - https://doi.org/10.1111/j.1742-1241.2012.02970.x DB - PRIME DP - Unbound Medicine ER -